NCT02399085 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 81
- units
- Participants
- groups
- description
- MOR00208: MOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle. LEN: Participants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings. On days when both study drugs were given together, LEN was administered prior to MOR00208.
- id
- BG000
- title
- Treatment (MOR00208, Lenalidomide)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 23
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 58
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.53
- value
- 69.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 37
- title
- Female
- measurements
- group Id
- BG000
- value
- 44
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 72
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 6
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- Czechia
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 13
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 9
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 11
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 15
- title
- Spain
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 81
- units
- Participants
- groups
- description
- MOR00208: MOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle. LEN: Participants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings. On days when both study drugs were given together, LEN was administered prior to MOR00208.
- id
- BG000
- title
- Treatment (MOR00208, Lenalidomide)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 23
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 58
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.53
- value
- 69.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 37
- title
- Female
- measurements
- group Id
- BG000
- value
- 44
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 72
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 6
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- Czechia
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 13
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 9
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 11
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 15
- title
- Spain
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle